Cited by 772Liver Disease Diagnosis and TreatmentAlcohol Consumption and Health EffectsLiver Diseases and Immunity

The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.

Association between noninvasive fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the United States

Open access

Kim, Donghee, Kim, Ray W., Kim, Hwa Jung, Therneau, Terry M.·2013·Hepatology

Open this paper in CoChat — free account Open PDF

Abstract

UNLABELLED: The clinical and public health significance of nonalcoholic fatty liver disease (NAFLD) is not well established. We investigated the long-term effect of NAFLD on mortality. This analysis utilized the National Health and Nutrition Examination Survey conducted in 1988-1994 and subsequent follow-up data for mortality through December 31, 2006. NAFLD was defined by ultrasonographic detection of hepatic steatosis in the absence of other known liver diseases. The presence and severity of hepatic fibrosis in subjects with NAFLD was determined by the NAFLD fibrosis score (NFS), the aspartate aminotransferase to platelet ratio index (APRI), and FIB-4 score. Of 11,154 participants, 34.0% had NAFLD--the majority (71.7%) had NFS consistent with lack of significant fibrosis (NFS <-1.455), whereas 3.2% had a score indicative of advanced fibrosis (NFS >0.676). After a median follow-up of 14.5 years, NAFLD was not associated with higher mortality (age- and sex-adjusted hazard ratio [HR]: 1.05; 95% confidence interval [CI]: 0.93-1.19). In contrast, there was a progressive increase in mortality with advancing fibrosis scores. Compared to subjects without fibrosis, those with a high probability of advanced fibrosis had a 69% increase in mortality (for NFS: HR, 1.69, 95% CI: 1.09-2.63; for APRI: HR, 1.85, 95% CI: 1.02-3.37; for FIB-4: HR, 1.66, 95% CI: 0.98-2.82) after adjustment for other known predictors of mortality. These increases in mortality were almost entirely from cardiovascular causes (for NFS: HR, 3.46, 95% CI: 1.91-6.25; for APRI: HR, 2.53, 95% CI: 1.33-4.83; for FIB-4: HR, 2.68, 95% CI: 1.44-4.99). CONCLUSIONS: Ultrasonography-diagnosed NAFLD is not associated with increased mortality. However, advanced fibrosis, as determined by noninvasive fibrosis marker panels, is a significant predictor of mortality, mainly from cardiovascular causes, independent of other known factors.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1002/hep.26156

Cites

37 of 37 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791
Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection†‡
Sterling, R. K., Lissen, E., Clumeck, N., Sola, R., Correa, M. C., Montaner, J., S. Sulkowski, M., Torriani, F. J., Dieterich, D. T., Thomas, D. L., et al. (2006) · Hepatology · doi:10.1002/hep.21178 · Cited by 5,021
A Simple Noninvasive Index Can Predict Both Significant Fibrosis and Cirrhosis in Patients With Chronic Hepatitis C
Wai, C.-T., Greenson, J. K., Fontana, R. J., Kalbfleisch, J. D., Marrero, J. A., Conjeevaram, H. S., & Lok, A. S.-F. (2003) · Hepatology · doi:10.1053/jhep.2003.50346 · Cited by 4,406
The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association
Chalasani, N., Younossi, Z. M., Lavine, J. E., Diehl, A. M., Brunt, E. M., Cusi, K. J., Charlton, M., & Sanyal, A. J. (2012) · Hepatology · doi:10.1002/hep.25762 · Cited by 3,854
Prevalence of Hepatic Steatosis in An Urban Population in the United States: Impact of Ethnicity
Browning, J. D., Szczepaniak, L. S., Dobbins, R., Nuremberg, P., Horton, J. D., Cohen, J. C., Grundy, S. M., & Hobbs, H. H. (2004) · Hepatology · doi:10.1002/hep.20466 · Cited by 3,664
The NAFLD fibrosis score
Angulo, P., Hui, J. M., Marchesini, G., Bugianesi, E., George, J., Farrell, G. C., Enders, F., Saksena, S., Burt, A. D., Bida, J. P., et al. (2007) · Hepatology · doi:10.1002/hep.21496 · Cited by 3,244
Self-citation
Systematic review: the epidemiology and natural history of non‐alcoholic fatty liver disease and non‐alcoholic steatohepatitis in adults
Vernon, G. C., Baranova, A. V., & Younossi, Z. M. (2011) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2011.04724.x · Cited by 3,116
The Natural History of Nonalcoholic Fatty Liver Disease: A Population-Based Cohort Study
Adams, L. A., Lymp, J. F., St. Sauver, J., Sanderson, S. O., Lindor, K. D., Feldstein, A., & Angulo, P. (2005) · Gastroenterology · doi:10.1053/j.gastro.2005.04.014 · Cited by 2,890
Long-term follow-up of patients with NAFLD and elevated liver enzymes
Ekstedt, M., Franzén, L. E., Mathiesen, U. L., Thorelius, L., Holmqvist, M., Bodemar, G., & Kechagias, S. (2006) · Hepatology · doi:10.1002/hep.21327 · Cited by 2,302
FIB-4
Vallet‐Pichard, A., Mallet, V. O., Nalpas, B., Verkarre, V., Nalpas, A., Dhalluin-Venier, V., Fontaine, H., & Pol, S. (2007) · Hepatology · doi:10.1002/hep.21669 · Cited by 2,085

Show all 37 references

Sorted by citations

EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease
(2016) · Journal of Hepatology · doi:10.1016/j.jhep.2015.11.004 · Cited by 4,836
NAFLD: A multisystem disease
Byrne, C. D., & Targher, G. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2014.12.012 · Cited by 3,144
Fibrosis stage is the strongest predictor for disease‐specific mortality in NAFLD after up to 33 years of follow‐up
Ekstedt, M., Hagström, H., Nasr, P., Fredrikson, M., Stål, P., Kechagias, S., & Hultcrantz, R. (2015) · Hepatology · doi:10.1002/hep.27368 · Cited by 2,287
The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis
Riazi, K., Azhari, H., Charette, J. H., Underwood, F. E., King, J. A., Afshar, E. E., Swain, M. G., Congly, S. E., Kaplan, G. G., & Shaheen, A.-A. (2022) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(22)00165-0 · Cited by 2,246
Global burden of liver disease: 2023 update
Devarbhavi, H., Asrani, S. K., Arab, J. P., Nartey, Y. A., Pose, E., & Kamath, P. S. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.03.017 · Cited by 2,267
EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD).
Tacke, F., Horn, P., Wai-Sun Wong, V., Ratziu, V., Bugianesi, E., Francque, S., Zelber-Sagi, S., Valenti, L., Roden, M., Schick, F., et al. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2024.04.031 · Cited by 2,210
EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis – 2021 update
Berzigotti, A., Tsochatzis, E., Boursier, J., Castera, L., Cazzagon, N., Friedrich-Rust, M., Petta, S., & Thiele, M. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2021.05.025 · Cited by 1,925
EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis
(2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.04.006 · Cited by 1,875
Noninvasive assessment of liver disease in patients with nonalcoholic fatty liver disease
Castera, L., Friedrich-Rust, M., & Loomba, R. (2019) · Gastroenterology · doi:10.1053/j.gastro.2018.12.036 · Cited by 1,494
Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: A meta-analysis
Targher, G., Byrne, C. D., Lonardo, A., Zoppini, G., & Barbui, C. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.05.013 · Cited by 1,429
Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases
Adams, L. A., Anstee, Q. M., Tilg, H., & Targher, G. (2017) · Gut · doi:10.1136/gutjnl-2017-313884 · Cited by 1,224
Sex Differences in Nonalcoholic Fatty Liver Disease: State of the Art and Identification of Research Gaps
Lonardo, A., Nascimbeni, F., Ballestri, S., Fairweather, D., Win, S., Than, T. A., Abdelmalek, M. F., & Suzuki, A. (2019) · Hepatology · doi:10.1002/hep.30626 · Cited by 1,095
Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999–2019: a systematic review and meta-analysis
Li, J., Zou, B., Yeo, Y. H., Feng, Y., Xie, X., Lee, D. H., Fujii, H., Wu, Y., Kam, L. Y., Ji, F., et al. (2019) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(19)30039-1 · Cited by 1,036
The Prevalence of Non-Alcoholic Fatty Liver Disease in Children and Adolescents: A Systematic Review and Meta-Analysis
Anderson, E. L., Howe, L. D., Jones, H. E., Higgins, J. P. T., Lawlor, D. A., & Fraser, A. (2015) · PLoS ONE · doi:10.1371/journal.pone.0140908 · Cited by 902
Hypertension, diabetes, atherosclerosis and NASH: Cause or consequence?
Lonardo, A., Nascimbeni, F., Mantovani, A., & Targher, G. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.09.021 · Cited by 753
Clinical epidemiology and disease burden of nonalcoholic fatty liver disease
Perumpail, B. J., Khan, M. A., Yoo, E. R., Cholankeril, G. T., Kim, D., & Ahmed, A. (2017) · World Journal of Gastroenterology · doi:10.3748/wjg.v23.i47.8263 · Cited by 759
Self-citation
2019 Global NAFLD Prevalence: A Systematic Review and Meta-analysis
Le, M. H., Yeo, Y. H., Li, X., Li, J., Zou, B., Wu, Y., Ye, Q., Huang, D. Q., Zhao, C., Zhang, J., et al. (2022) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2021.12.002 · Cited by 711
Role of Dietary Fructose and Hepatic De Novo Lipogenesis in Fatty Liver Disease
Softic, S., Cohen, D. E., & Kahn, C. R. (2016) · Digestive Diseases and Sciences · doi:10.1007/s10620-016-4054-0 · Cited by 709
Limitations of liver biopsy and non-invasive diagnostic tests for the diagnosis of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis
Sumida, Y. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i2.475 · Cited by 708
Mortality in biopsy-confirmed nonalcoholic fatty liver disease: results from a nationwide cohort
Simon, T. G., Roelstraete, B., Khalili, H., Hagström, H., & Ludvigsson, J. F. (2021) · Gut · doi:10.1136/gutjnl-2020-322786 · Cited by 673
EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease
European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), & European Association for the Study of Obesity (EASO) (2016) · Diabetologia · doi:10.1007/s00125-016-3902-y · Cited by 695
Non-alcoholic fatty liver disease and risk of fatal and non-fatal cardiovascular events: an updated systematic review and meta-analysis
Mantovani, A., Csermely, A., Petracca, G., Beatrice, G., Corey, K. E., Simon, T. G., Byrne, C. D., & Targher, G. (2021) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(21)00308-3 · Cited by 674
NAFLD and cardiovascular diseases: a clinical review
Kasper, P., Martin, A., Lang, S., Kütting, F., Goeser, T., Demir, M., & Steffen, H. (2020) · Clinical Research in Cardiology · doi:10.1007/s00392-020-01709-7 · Cited by 685
The Natural Course of Non-Alcoholic Fatty Liver Disease
Bertot, L. C., & Adams, L. A. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17050774 · Cited by 638
Non-invasive assessment of non-alcoholic fatty liver disease: Clinical prediction rules and blood-based biomarkers
Gómez, E. V., & Chalasani, N. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.11.013 · Cited by 608
The epidemiology of non‐alcoholic fatty liver disease
Bellentani, S. (2017) · Liver international (Print) · doi:10.1111/liv.13299 · Cited by 416
Extrahepatic complications of nonalcoholic fatty liver disease
Armstrong, M. J., Adams, L. A., Canbay, A. E., & Syn, W. (2013) · Hepatology · doi:10.1002/hep.26717 · Cited by 617
Addressing liver disease in the UK: a blueprint for attaining excellence in health care and reducing premature mortality from lifestyle issues of excess consumption of alcohol, obesity, and viral hepatitis
Williams, R. L., Aspinall, R., Bellis, M. A., Camps-Walsh, G., Cramp, M., Dhawan, A. K., Ferguson, J., Forton, D. M., Foster, G. R., Gilmore, S. I., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(14)61838-9 · Cited by 601
Complications, morbidity and mortality of nonalcoholic fatty liver disease
Mantovani, A., Scorletti, E., Mosca, A., Alisi, A., Byrne, C. D., & Targher, G. (2020) · Metabolism · doi:10.1016/j.metabol.2020.154170 · Cited by 575
EASL-EASD-EASO Clinical Practice Guidelines for the Management of Non-Alcoholic Fatty Liver Disease
European Association for the Study of the Liver (EASL), E. A. F. T. S. O. D. (. (2016) · Obesity Facts · doi:10.1159/000443344 · Cited by 531
Asia–Pacific Working Party on Non‐alcoholic Fatty Liver Disease guidelines 2017—Part 1: Definition, risk factors and assessment
Wong, V. W., Chan, W., Chitturi, S., Chawla, Y. K., Dan, Y. Y., Duseja, A. K., Fan, J., Goh, K., Hamaguchi, M., Hashimoto, E., et al. (2017) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.13857 · Cited by 513
EASL-EASD-EASO Clinical Practice Guidelines on the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
(2024) · Obesity Facts · doi:10.1159/000539371 · Cited by 522
Sarcopenia is an independent risk factor for non-alcoholic steatohepatitis and significant fibrosis
Koo, B. K., Kim, D., Joo, S. K., Kim, J. H., Chang, M. S., Kim, B. G., Lee, K. L., & Kim, W. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2016.08.019 · Cited by 440
Self-citation
Nonalcoholic Fatty Liver Disease and the Heart
Stahl, E. P., Dhindsa, D. S., Lee, S. K., Sandesara, P. B., Chalasani, N., & Sperling, L. S. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.11.050 · Cited by 482
Diagnostic modalities for nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and associated fibrosis
Younossi, Z. M., Loomba, R. S., Anstee, Q. M., Rinella, M. E., Bugianesi, E., Marchesini, G., Neuschwander‐Tetri, B. A., Serfaty, L., Negro, F., Caldwell, S. H., et al. (2017) · Hepatology · doi:10.1002/hep.29721 · Cited by 431
Metabolic dysfunction-associated fatty liver disease is associated with increased all-cause mortality in the United States
Kim, D., Konyn, P., Sandhu, K. K., Dennis, B. B., Cheung, A. C., & Ahmed, A. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2021.07.035 · Cited by 417
Self-citation
Systematic review with meta-analysis: non-invasive assessment of non-alcoholic fatty liver disease--the role of transient elastography and plasma cytokeratin-18 fragments
Kwok, R., Tse, Y. ‐., Wong, G. L. ‐., Ha, Y., Lee, A. U., Ngu, M. C., Chan, H. L. ‐., & Wong, V. W. ‐. (2014) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.12569 · Cited by 405
Epidemiology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis: Implications for Liver Transplantation
Younossi, Z. M., Marchesini, G., Cortez‐Pinto, H., & Petta, S. (2018) · Transplantation · doi:10.1097/tp.0000000000002484 · Cited by 405
Diagnostic accuracy and prognostic significance of blood fibrosis tests and liver stiffness measurement by FibroScan in non-alcoholic fatty liver disease
Boursier, J., Vergniol, J., Guillet, A., Hiriart, J.-B., Lannes, A., Le Bail, B., Michalak, S., Chermak, F., Bertrais, S., Foucher, J., et al. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.04.023 · Cited by 400
Management of NAFLD: a stage-based approach
Rinella, M. E., & Sanyal, A. J. (2016) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2016.3 · Cited by 393
Gender and menopause impact severity of fibrosis among patients with nonalcoholic steatohepatitis
Yang, J. D., Abdelmalek, M. F., Pang, H., Guy, C. D., Smith, A. D., Diehl, A. M., & Suzuki, A. (2014) · Hepatology · doi:10.1002/hep.26761 · Cited by 374
Nonalcoholic fatty liver disease incidence and impact on metabolic burden and death: A 20 year‐community study
Allen, A. M., Therneau, T. M., Larson, J. J., Coward, A., Somers, V. K., & Kamath, P. S. (2017) · Hepatology · doi:10.1002/hep.29546 · Cited by 372
Self-citation
Advanced Liver Fibrosis Is Common in Patients With Type 2 Diabetes Followed in the Outpatient Setting: The Need for Systematic Screening
Lomonaco, R., Godinez Leiva, E., Bril, F., Shrestha, S., Mansour, L., Budd, J., Portillo Romero, J., Schmidt, S., Chang, K.-L., Samraj, G., et al. (2021) · Diabetes Care · doi:10.2337/dc20-1997 · Cited by 354
Challenges and opportunities in drug and biomarker development for nonalcoholic steatohepatitis: Findings and recommendations from an American Association for the Study of Liver Diseases–U.S. Food and Drug Administration Joint Workshop
Sanyal, A. J., Friedman, S. L., McCullough, A. J., & Dimick‐Santos, L. (2014) · Hepatology · doi:10.1002/hep.27678 · Cited by 360
Sarcopaenia is associated with NAFLD independently of obesity and insulin resistance: Nationwide surveys (KNHANES 2008–2011)
Lee, Y., Jung, K. S., Kim, S. U., Yoon, H.-J., Yun, Y., Lee, B., Kang, E. S., Han, K., Lee, H. C., & Soo, B. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.02.051 · Cited by 340
Nonobese fatty liver disease
Kim, D., & Kim, W. R. (2017) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2016.08.028 · Cited by 341
Self-citation
From NAFLD in clinical practice to answers from guidelines
Nascimbeni, F., Pais, R., Bellentani, S., Day, C. P., Ratziu, V., Loria, P., & Lonardo, A. (2013) · Journal of Hepatology · doi:10.1016/j.jhep.2013.05.044 · Cited by 345
Association between non-alcoholic fatty liver disease and cancer incidence rate.
Kim, G.-A., Lee, H.-C., Choe, J., Kim, M.-J., Lee, M. J., Chang, H.-S., Bae, I. Y., Kim, H., An, J., Shim, J., et al. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.09.012 · Cited by 311
Self-citation
Effect of metabolic traits on the risk of cirrhosis and hepatocellular cancer in nonalcoholic fatty liver disease
Kanwal, F., Kramer, J. R., Li, L., Dai, J., Natarajan, Y., Yu, X., Asch, S. M., & El‐Serag, H. B. (2020) · Hepatology · doi:10.1002/hep.31014 · Cited by 319
Hepatic Gene Expression Profiles Differentiate Presymptomatic Patients With Mild Versus Severe Nonalcoholic Fatty Liver Disease
Moylan, C. A., Pang, H., Dellinger, A. E., Suzuki, A., Garrett, M. E., Guy, C. D., Murphy, S. K., Ashley‐Koch, A. E., Choi, S. S., Michelotti, G. A., et al. (2013) · Hepatology · doi:10.1002/hep.26661 · Cited by 319
The risk of incident extrahepatic cancers is higher in non-alcoholic fatty liver disease than obesity – A longitudinal cohort study
Allen, A. M., Hicks, S. B., Mara, K. C., Larson, J. J., & Therneau, T. M. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2019.08.018 · Cited by 318
Self-citation
Natural history and progression of metabolic dysfunction-associated steatotic liver disease
Hagström, H., Shang, Y., Hegmar, H., & Nasr, P. (2024) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(24)00193-6 · Cited by 310
Population screening for liver fibrosis: Toward early diagnosis and intervention for chronic liver diseases
Ginès, P., Castéra, L., Lammert, F., Graupera, I., Serra‐Burriel, M., Allen, A. M., Wong, V. W., Hartmann, P., Thiele, M. S., Caballería, L., et al. (2021) · Hepatology · doi:10.1002/hep.32163 · Cited by 296
Prospective evaluation of the prevalence of non-alcoholic fatty liver disease and steatohepatitis in a large middle-aged US cohort
Harrison, S. A., Gawrieh, S., Roberts, K., Lisanti, C. J., Schwope, R. B., Cebe, K. M., Paradis, V., Bedossa, P., Aldridge Whitehead, J. M., Labourdette, A., et al. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2021.02.034 · Cited by 293
Prevalence of non-alcoholic fatty liver disease and risk factors for advanced fibrosis and mortality in the United States
Le, M. H., Devaki, P., Ha, N. B., Jun, D. W., Te, H. S., Cheung, R. C., & Nguyen, M. H. (2017) · PLoS ONE · doi:10.1371/journal.pone.0173499 · Cited by 287
Noninvasive evaluation of NAFLD
Castéra, L., Vilgrain, V., & Angulo, P. (2013) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2013.175 · Cited by 272
KASL clinical practice guidelines: Management of nonalcoholic fatty liver disease
Kang, S. H., Lee, H. W., Yoo, J., Cho, Y., Kim, S. U., Lee, T. H., Jang, B. K., Ahn, S. B., Ahn, S. B., Kim, H., et al. (2021) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2021.0178 · Cited by 276
Self-citation
Risk of cardiovascular, cardiac and arrhythmic complications in patients with non-alcoholic fatty liver disease
Ballestri, S. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i7.1724 · Cited by 264
Liver fibrosis scores predict liver disease mortality in the United States population
Ünalp–Arida, A., & Ruhl, C. E. (2017) · Hepatology · doi:10.1002/hep.29113 · Cited by 261
Hepatocyte Notch activation induces liver fibrosis in nonalcoholic steatohepatitis
Zhu, C., Kim, K., Wang, X., Bartolome, A., Salomao, M., Dongiovanni, P., Meroni, M., Graham, M. J., Yates, K. P., Diehl, A. M., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aat0344 · Cited by 250
The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement
Athyros, V. G., Alexandrides, T. K., Bilianou, H., Cholongitas, E., Doumas, M., Ganotakis, E. S., Goudevenos, J., Elisaf, M. S., Germanidis, G., Giouleme, O., et al. (2017) · Metabolism · doi:10.1016/j.metabol.2017.02.014 · Cited by 219
Nonalcoholic Fatty Liver Disease and Fibrosis Associated With Increased Risk of Cardiovascular Events in a Prospective Study
Baratta, F., Pastori, D., Angelico, F., Balla, A., Paganini, A. M., Cocomello, N., Ferro, D., Violi, F., Sanyal, A. J., & Ben, M. D. (2019) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2019.12.026 · Cited by 252
Non-Alcoholic Fatty Liver Disease
Engin, A. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-48382-5_19 · Cited by 253
Prevalence of Nonalcoholic Steatohepatitis-Associated Cirrhosis in the United States: An Analysis of National Health and Nutrition Examination Survey Data
Kabbany, M. N., Selvakumar, P. K. C., Watt, K. D. S., López, R., Akras, Z., Zein, N. N., Carey, W., & Alkhouri, N. (2017) · The American Journal of Gastroenterology · doi:10.1038/ajg.2017.5 · Cited by 241
Nonalcoholic Fatty Liver Disease and Metabolic Syndrome
Kim, D., Touros, A., & Kim, W. R. (2017) · Clinics in Liver Disease · doi:10.1016/j.cld.2017.08.010 · Cited by 239
Self-citation
Comparison of FIB‐4 index, NAFLD fibrosis score and BARD score for prediction of advanced fibrosis in adult patients with non‐alcoholic fatty liver disease: A meta‐analysis study
Sun, W., Cui, H., Li, N., Wei, Y., Lai, S., Yang, Y., Yin, X., & Chen, D. (2016) · Hepatology Research · doi:10.1111/hepr.12647 · Cited by 236
MAFLD: a multisystem disease
Pipitone, R. M., Ciccioli, C., Infantino, G., Mantia, C. L., Parisi, S., Tulone, A., Pennisi, G., Grimaudo, S., & Petta, S. (2023) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/20420188221145549 · Cited by 248
Non-alcoholic fatty liver disease and risk of cardiovascular disease
Lonardo, A., Sookoian, S. C., Pirola, C. J., & Targher, G. (2015) · Metabolism · doi:10.1016/j.metabol.2015.09.017 · Cited by 236
Changing trends in etiology‐based annual mortality from chronic liver disease, from 2007 through 2016
Kim, D., Li, A. A., Gadiparthi, C., Khan, M. A., Cholankeril, G., Glenn, J. S., & Ahmed, A. (2018) · Gastroenterology · doi:10.1053/j.gastro.2018.07.008 · Cited by 223
Self-citation
Pathophysiological Molecular Mechanisms of Obesity: A Link between MAFLD and NASH with Cardiovascular Diseases
Gutiérrez‐Cuevas, J., Santos, A., & Armendáriz‐Borunda, J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222111629 · Cited by 227
Burden of Illness and Economic Model for Patients With Nonalcoholic Steatohepatitis in the United States
Younossi, Z. M., Tampi, R. P., Priyadarshini, M., Nader, F., Younossi, I. M., & Racila, A. (2018) · Hepatology · doi:10.1002/hep.30254 · Cited by 212
Non-alcoholic fatty liver disease: What the clinician needs to know
Machado, M. V. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i36.12956 · Cited by 215
Contributing roles of mitochondrial dysfunction and hepatocyte apoptosis in liver diseases through oxidative stress, post-translational modifications, inflammation, and intestinal barrier dysfunction
LeFort, K. R., Rungratanawanich, W., & Song, B.-J. (2024) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-023-05061-7 · Cited by 202
NAFLD and Chronic Kidney Disease
Marcuccilli, M. E., & Chonchol, M. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17040562 · Cited by 201
Prevalence of clinically significant liver disease within the general population, as defined by non-invasive markers of liver fibrosis: a systematic review
Harris, R., Harman, D. J., Card, T. R., Aithal, G. P., & Guha, I. N. (2017) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(16)30205-9 · Cited by 203
Nonalcoholic fatty liver disease: Evolving paradigms
Lonardo, A., Nascimbeni, F., Maurantonio, M., Marrazzo, A., Rinaldi, L., & Adinolfi, L. E. (2017) · World Journal of Gastroenterology · doi:10.3748/wjg.v23.i36.6571 · Cited by 204
Nonalcoholic fatty liver disease and vascular disease: State-of-the-art
Fargion, S. R. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i37.13306 · Cited by 197
Nonalcoholic fatty liver disease - A multisystem disease?
Mikolašević, I., Milić, S., Wensveen, T. T., Grgić, I., Jakopčić, I., Štimac, D., Wensveen, F. M., & Orlić, L. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i43.9488 · Cited by 195
Subclinical hypothyroidism and low-normal thyroid function are associated with nonalcoholic steatohepatitis and fibrosis
Kim, D., Kim, W., Joo, S. K., Bae, J. M., Kim, J. H., & Ahmed, A. (2018) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2017.08.014 · Cited by 191
Self-citation
Metabolic Phenotyping and Systems Biology Approaches to Understanding Metabolic Syndrome and Fatty Liver Disease
Dumas, M., Kinross, J. K., & Nicholson, J. K. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.11.001 · Cited by 187
Effect of semaglutide on liver enzymes and markers of inflammation in subjects with type 2 diabetes and/or obesity
Newsome, P., Francque, S., Harrison, S., Ratziu, V., Van Gaal, L., Calanna, S., Hansen, M., Linder, M., & Sanyal, A. (2019) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.15316 · Cited by 186
Lipoprotein Metabolism, Dyslipidemia, and Nonalcoholic Fatty Liver Disease
Fisher, E. A. A., & Cohen, D. E. (2013) · Seminars in Liver Disease · doi:10.1055/s-0033-1358519 · Cited by 189
Nonalcoholic fatty liver disease and mortality from all causes, cardiovascular disease, and cancer: a meta-analysis
Liu, Y., Zhong, G.-C., Tan, H.-Y., Hao, F.-B., & Hu, J.-J. (2019) · Scientific Reports · doi:10.1038/s41598-019-47687-3 · Cited by 176
Body Fat Distribution and Risk of Incident and Regressed Nonalcoholic Fatty Liver Disease
Kim, D., Chung, G. E., Kwak, M., Seo, H. B., Kang, J. H., Kim, W. K., Kim, Y. J., Yoon, J., Lee, H.-S., & Kim, C. Y. (2015) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2015.07.024 · Cited by 175
Self-citation
Inadequate physical activity and sedentary behavior are independent predictors of nonalcoholic fatty liver disease
Kim, D., Vazquez‐Montesino, L. M., Li, A. A., Cholankeril, G., & Ahmed, A. (2020) · Hepatology · doi:10.1002/hep.31158 · Cited by 177
Self-citation
Non-alcoholic Fatty Liver Disease: Growing Burden, Adverse Outcomes and Associations
Kumar, R., Priyadarshi, R., & Anand, U. (2019) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2019.00051 · Cited by 176
Advanced fibrosis is associated with incident cardiovascular disease in patients with non‐alcoholic fatty liver disease
Henson, J. B., Simon, T. G., Kaplan, A. J., Osganian, S. A., Masia, R., & Corey, K. E. (2020) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.15660 · Cited by 166
Liver fibrosis in non-alcoholic fatty liver disease - diagnostic challenge with prognostic significance
Stal, P. I. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v21.i39.11077 · Cited by 162
Healthcare and socioeconomic costs of NAFLD: A global framework to navigate the uncertainties
Allen, A. M., Lazarus, J. V., & Younossi, Z. M. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.01.026 · Cited by 156
Current and Future Burden of Chronic Nonmalignant Liver Disease
Udompap, P., Kim, D., & Kim, W. R. (2015) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2015.08.015 · Cited by 153
Self-citation
Noninvasive assessment of liver fibrosis in NAFLD
Sanyal, A. J., Castera, L., & Wong, V. W.-S. (2023) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2023.03.042 · Cited by 157
Predictive Role of Neutrophil-Percentage-to-Albumin Ratio (NPAR) in Nonalcoholic Fatty Liver Disease and Advanced Liver Fibrosis in Nondiabetic US Adults: Evidence from NHANES 2017–2018
Liu, C.-F., & Chien, L.-W. (2023) · Nutrients · doi:10.3390/nu15081892 · Cited by 152
Type 2 diabetes mellitus increases the risk of hepatic fibrosis in individuals with obesity and nonalcoholic fatty liver disease
Barb, D., Repetto, E., Stokes, M. E., Shankar, S. S., & Cusi, K. J. (2021) · Obesity · doi:10.1002/oby.23263 · Cited by 148
Twelve week liraglutide or sitagliptin does not affect hepatic fat in type 2 diabetes: a randomised placebo-controlled trial
Smits, M. M., Tonneijck, L., Muskiet, M. H. A., Kramer, M. H. H., Pouwels, P. J. W., Pieters-van den Bos, I. C., Hoekstra, T., Diamant, M., van Raalte, D. H., & Cahen, D. L. (2016) · Diabetologia · doi:10.1007/s00125-016-4100-7 · Cited by 142
NAFLD and Extra-Hepatic Comorbidities: Current Evidence on a Multi-Organ Metabolic Syndrome
Rosato, V., Masarone, M., Dallio, M., Federico, A., Aglitti, A., & Persico, M. (2019) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph16183415 · Cited by 130
The combination of liver stiffness measurement and NAFLD fibrosis score improves the noninvasive diagnostic accuracy for severe liver fibrosis in patients with nonalcoholic fatty liver disease
Petta, S., Vanni, E., Bugianesi, E., Marco, V. D., Cammà, C., Cabibi, D., Mezzabotta, L., & Craxı̀, A. (2014) · Liver International · doi:10.1111/liv.12584 · Cited by 137
Energy-matched moderate and high intensity exercise training improves nonalcoholic fatty liver disease risk independent of changes in body mass or abdominal adiposity — A randomized trial
Winn, N. C., Liu, Y., Rector, R. S., Parks, E. J., Ibdah, J. A., & Kanaley, J. A. (2017) · Metabolism · doi:10.1016/j.metabol.2017.08.012 · Cited by 138
Current Status in Testing for Nonalcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH)
Drescher, H. K., Weiskirchen, S., & Weiskirchen, R. (2019) · Cells · doi:10.3390/cells8080845 · Cited by 134
NAFLD and Diabetes: Two Sides of the Same Coin? Rationale for Gene-Based Personalized NAFLD Treatment
Xia, M., Bian, H., & Gao, X. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00877 · Cited by 139
Accuracy of noninvasive scoring systems in assessing risk of death and liver-related endpoints in patients with nonalcoholic fatty liver disease
Hagström, H., Nasr, P., Ekstedt, M., Stål, P., Hultcrantz, R., & Kechagias, S. (2019) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2018.11.030 · Cited by 132

Authors: Kim, D., Kim, R. W., Kim, H. J., & Therneau, T. M.
Affiliations: Mayo Clinic (US)
Asan Medical Center (KR)
ORCID: Kim, Donghee
Kim, Hwa Jung
Therneau, Terry M.
Venue: Hepatology
Publisher: Ovid Technologies (Wolters Kluwer Health)
Published: 2013-04
Volume: 57
Issue: 4
Pages: 1357-1365
ISSN: 0270-9139 (ISSN-L)
DOI: 10.1002/hep.26156
PMC: PMC3622816
OpenAlex: W1987934823
Cited by: 772
References: 37
Citations by year: 2026: 27 · 2025: 35 · 2024: 51 · 2023: 74 · 2022: 77 · 2021: 80 · 2020: 92 · 2019: 74 · 2018: 52 · 2017: 70 · 2016: 43 · 2015: 46 · 2014: 33 · 2013: 18
FWCI: 23.23
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: doi.wiley.com/10.1002/tdm_license_1.1 (tdm, 883 d)
Locations: Hepatology (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
Funders: National Institute of Diabetes, Digestive, and Kidney Disease (DK-34238)
Topics: Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
Health Sciences › Medicine › Pathology and Forensic Medicine › Alcohol Consumption and Health Effects
Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
Keywords: non-alcoholic fatty liver disease, liver fibrosis, mortality, NAFLD fibrosis score, APRI, FIB-4, cardiovascular mortality, hepatic steatosis, non-invasive fibrosis markers, long-term follow-up, NHANES cohort, liver transplantation, liver cancer
MeSH terms: Adult, Aged, Aspartate Aminotransferases, Blood Platelets, Fatty Liver, Female, Follow-Up Studies, Humans, Liver, Liver Cirrhosis, Male, Middle Aged, Nutrition Surveys, Retrospective Studies, Risk Factors, Severity of Illness Index, Ultrasonography, United States, Prevalence, Survival Rate, Non-alcoholic Fatty Liver Disease

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Association between noninvasive fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the United States

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks